How to buy Bristol-Myers Squibb (BMY) shares in the UK

Learn how to easily invest in Bristol-Myers Squibb shares.

Bristol-Myers Squibb Company
NYSE: BMY - USD
DRUG MANUFACTURERS-GENERAL
$61.31
+ $0.08 ( + 0.13%)

Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers-general business based in the US. It opened the day at $60.51 after a previous close of $61.23. During the day the price has varied from a low of $60.36 to a high of $61.415. The latest price was $61.31 (25 minute delay). Bristol-Myers Squibb is listed on the NYSE and employs 30,250 staff. All prices are listed in US Dollars.

How to buy shares in Bristol-Myers Squibb

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BMY in this case.
  5. Research Bristol-Myers Squibb shares. The platform should provide the latest information available.
  6. Buy your Bristol-Myers Squibb shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Bristol-Myers Squibb's share price?

Since the stock market crash that started in February 2020, Bristol-Myers Squibb's share price has had significant negative movement.

Its last market close was $61.31, which is 6.58% down on its pre-crash value of $65.63 and 33.98% up on the lowest point reached during the March 2020 crash when the shares fell as low as $45.76.

If you had bought $1,000 worth of Bristol-Myers Squibb shares at the start of February 2020, those shares would have been worth $729.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $964.41.

Bristol-Myers Squibb share price (NYSE:BMY)

Use our graph to track the performance of BMY stocks over time.

Bristol-Myers Squibb shares at a glance

Information last updated 2021-09-17.
Open$60.51
High$61.415
Low$60.36
Close$61.31
Previous close$61.23
Change$0.08
Change %0.1307%
Volume20,450,495
Information last updated 2021-09-17.
52-week range$55.1871 - $69.75
50-day moving average$66.6574
200-day moving average$65.3036
Wall St. target price$80.24
Dividend yield$1.92 (3.14%)
Earnings per share (TTM)$-2.264
Promoted
eToro Free Stocks

Invest in Bristol-Myers Squibb shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 10x Bristol-Myers Squibb shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
Freetrade logo £0 No minimum £2.02
£450.38 total
Capital at risk
eToro Free Stocks logo £0 $50 £2.24
£450.60 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.91
£449.27 total
Capital at risk
Stake logo £0 £50 £2.27
£450.63 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £16.46
£464.82 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £14.74
£463.10 total
Capital at risk
Fineco logo £0 No minimum £4.48
£452.84 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £15.13
£463.49 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Bristol-Myers Squibb stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bristol-Myers Squibb price performance over time

Historical closes compared with the last close of $61.31

1 week (2021-09-13) -2.43%
1 month (2021-08-20) -11.40%
3 months (2021-06-18) -7.76%
6 months (2021-03-19) -2.22%
1 year (2020-09-18) 3.44%
2 years (2019-09-20) 21.24%
3 years (2018-09-20) -0.71%
5 years (2016-09-20) 10.35%

Is Bristol-Myers Squibb under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

PEG ratio

Bristol-Myers Squibb's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 14.5784. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Bristol-Myers Squibb's PEG ratio in relation to those of similar companies.

EBITDA

Bristol-Myers Squibb's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $18.8 billion (£13.8 billion).

The EBITDA is a measure of a Bristol-Myers Squibb's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Financials

Revenue TTM $44.4 billion
Operating margin TTM 18.55%
Gross profit TTM $34 billion
Return on assets TTM 4.31%
Return on equity TTM -11.76%
Profit margin -11.44%
Book value $16.564
Market capitalisation $136.2 billion

TTM: trailing 12 months

How to short and sell Bristol-Myers Squibb shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "BMY.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 20.3 million Bristol-Myers Squibb shares held short by investors – that's known as the "short interest". This figure is 7.2% down from 21.9 million last month.

There are a few different ways that this level of interest in shorting Bristol-Myers Squibb shares can be evaluated.

Short interest ratio (SIR)

Bristol-Myers Squibb's "short interest ratio" (SIR) is the quantity of Bristol-Myers Squibb shares currently shorted divided by the average quantity of Bristol-Myers Squibb shares traded daily (recently around 6.9 million). Bristol-Myers Squibb's SIR currently stands at 2.94. In other words for every 100,000 Bristol-Myers Squibb shares traded daily on the market, roughly 2940 shares are currently held short.

To gain some more context, you can compare Bristol-Myers Squibb's short interest ratio against those of similar companies.

However Bristol-Myers Squibb's short interest can also be evaluated against the total number of Bristol-Myers Squibb shares, or, against the total number of tradable Bristol-Myers Squibb shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bristol-Myers Squibb's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bristol-Myers Squibb shares in existence, roughly 10 shares are currently held short) or 0.0093% of the tradable shares (for every 100,000 tradable Bristol-Myers Squibb shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bristol-Myers Squibb.

Find out more about how you can short Bristol-Myers Squibb stock.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb.

Total ESG risk score

Bristol-Myers Squibb's total ESG risk: 29.16

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Bristol-Myers Squibb's total ESG risk score against those of similar companies.

Environmental score

Bristol-Myers Squibb's environmental score: 3.83/100

Bristol-Myers Squibb's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Bristol-Myers Squibb's social score: 18.82/100

Bristol-Myers Squibb's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Bristol-Myers Squibb's governance score: 14.02/100

Bristol-Myers Squibb's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Bristol-Myers Squibb's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Bristol-Myers Squibb scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb has, for the most part, managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.

Total ESG score 29.16
Total ESG percentile 52.58
Environmental score 3.83
Environmental score percentile 4
Social score 18.82
Social score percentile 4
Governance score 14.02
Governance score percentile 4
Level of controversy 2

Bristol-Myers Squibb share dividends

3.1%

Dividend yield: 3.14% of stock value

3.2%

Forward annual dividend yield: 3.2% of stock value

29.0%

Dividend payout ratio: 28.99% of net profits

Bristol-Myers Squibb has recently paid out dividends equivalent to 3.14% of its share value annually.

Bristol-Myers Squibb has paid out, on average, around 28.99% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.2% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 3.2% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb's case, that would currently equate to about $1.92 per share.

While Bristol-Myers Squibb's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

Bristol-Myers Squibb's most recent dividend payout was on 31 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2021 (the "ex-dividend date").

Bristol-Myers Squibb's dividend yield is perhaps best considered in relation to those of similar companies.

Have Bristol-Myers Squibb's shares ever split?

Bristol-Myers Squibb's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb shares which in turn could have impacted Bristol-Myers Squibb's share price.

Share price volatility

Over the last 12 months, Bristol-Myers Squibb's shares have ranged in value from as little as $55.1871 up to $69.75. A popular way to gauge a stock's volatility is its "beta".

BMY.US volatility(beta: 0.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb's is 0.5879. This would suggest that Bristol-Myers Squibb's shares are less volatile than average (for this exchange).

To put Bristol-Myers Squibb's beta into context you can compare it against those of similar companies.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site